LAV — 2021 Investments

3 investments dated 2021 · listed companies and verified rows first · show all

NiKang Therapeuticsnikangtx.comMay 2021

NiKang Therapeutics is a clinical-stage biotechnology company developing small molecule drugs for cancer, using structure-based drug design against targets such as HIF2α, CDK2, KRAS, and SHP2.

BiotechHealthtechWilmington, CN

Yan Lou(Founder)inZhenhai Gao(President, CEO, and Secretary)Hong (Kelsey) Chen(Chief Financial Officer)

BoardGary Yeung(Director)Ting Jia(Director)Roderick Wong(Director)

Co-investorsEcoR1 Capital HBM Healthcare Investments HBM Partners Lilly Asia Ventures RA Capital Samsara BioCapital +3 more

Qihan Biotechqihanbio.comMar 2021

Qihan Biotech uses multiplexable genome editing and immune shielding technologies in human stem cells and animal germline cells to develop immune-privileged cell and organ therapies.

BiotechDeep TechHealthtechHangzhou, CN

Luhan Yang, PhD(Co-Founder and Chief Executive Officer)George Church, PhD(Co-founder and Co-Chair of Qihan scientific advisory groups)Luhan Yang(Co-Founder & CEO)

Co-investorsAlta Partners ARCH Venture Partners Sequoia Capital

Sonoma Biotherapeuticssonomabio.com in 𝕏Jul 2021

Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.

BiotechHealthtechMedical DevicesSouth San Francisco, US

Jeffrey Bluestone(Founder)inJeff Bluestone, PhD(Founder and Scientific Advisor; co-founder and former President and CEO)Qizhi Tang, PhD(Founder and Scientific Advisor)Fred Ramsdell, PhD(Founder and Scientific Advisor)Alexander Rudensky, PhD(Founder and Scientific Advisor)Stephen Dilly, MBBS, PhD(President and Chief Executive Officer)

Co-investors8VC ARCH Venture Partners Frazier Life Sciences GV (Google Ventures)JDRF T1D Fund Lifeforce Capital +6 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.